This study aims to discuss the efficacy and safety of neoadjuvant chemotherapy with XELOX regimen (oxaliplatin plus capecitabine) .
Liver metastasis is the most important prognostic factor of colorectal cancer. Reasonable multidisciplinary therapy might improve the prognosis of patients with liver metastasis. Surgery has been the first choice under such situation. Recently, neoadjuvant chemotherapy has also shown its value in unresectable liver metastasis, for it can increase the chance of R0 resection and give some clues to chemosensitivity of agents. However, for those resectable lesions, the role and safety of neoadjuvant chemotherapy has yet to be confirmed. so we design this study.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
392
oxaliplatin: 130mg/m2, d1(Q3w) capecitabine:1000mg/m2 bid, d1-14(Q3w)
surgery with the aim of R0 resection
Peking University, School of Oncology
Beijing, Beijing Municipality, China
RECRUITINGPeking University, People's Hospital
Beijing, China
RECRUITINGdisease free survival rate
Time frame: 3 year
R0 resection rate
Time frame: at the time of pathological report
survival rate and over survival
Time frame: 5 year
surgery related mortality
Time frame: peri-operation period
response rate and safety of XELOX as a neoadjuvant regimen
Time frame: no time frame
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.